• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Immunogenicity of alefacept seen as minimal

Article

New Orleans - Following treatment with IV- or IM-administered alefacept (Amevive), more than 1,000 patients with chronic plaque psoriasis showed insignificant levels of drug-related antibody.

Recent Videos
Related Content
SPROUT Trial Highlights Benefits of Apremilast for Pediatric Psoriasis

SPROUT Trial Highlights Benefits of Apremilast for Pediatric Psoriasis

Article
The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

Podcast
Availability of Apremilast in US for Pediatric Patients Opens Avenues for Expanded Treatment Options and Oral Therapy

Availability of Apremilast in US for Pediatric Patients Opens Avenues for Expanded Treatment Options and Oral Therapy

Article
The Cutaneous Connection

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

Podcast
DPCP Immunotherapy Yields 61.8% Hair Regrowth Rate in Pediatric Alopecia Areata

DPCP Immunotherapy Yields 61.8% Hair Regrowth Rate in Pediatric Alopecia Areata

Article
“My Skin My Story” Provides Creative Outlet for Young Patients With Eczema

“My Skin My Story” Provides Creative Outlet for Young Patients With Eczema

Article
© 2024 MJH Life Sciences

All rights reserved.